Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The fatty liver in AIDS.

Phyllis C Tien1, Carl Grunfeld

  • 1Metabolism Section, Veterans Affairs Medical Center, San Francisco, CA 94121, USA. ptien@medicine.ucsf.edu

Seminars in Gastrointestinal Disease
|April 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between plasma concentrations of integrase strand transfer inhibitors and body weight gain in women with HIV.

AIDS (London, England)·2026
Same author

Associations Between Cannabis Use and Inflammatory Biomarkers Among People with HIV.

Cannabis and cannabinoid research·2026
Same author

High Enrollment and Representativeness of MACS and WIHS Study Participants in the newly merged MACS/WIHS Combined Cohort Study (MWCCS).

AJE advances : research in epidemiology·2026
Same author

Associations Between Sustained Methamphetamine/Amphetamine Use and Left Ventricular Dysfunction in a Cohort of Women Living With and Without HIV.

Journal of the American Heart Association·2026
Same author

Antiretroviral therapy switch among Medicare beneficiaries with HIV.

Journal of managed care & specialty pharmacy·2026
Same author

Cardiovascular Disease Risk and Falls in Men and Women Living With and Without HIV in MACS/WIHS Combined Cohort Study.

Journal of acquired immune deficiency syndromes (1999)·2026

Fatty liver in HIV patients stems from various factors, including the virus and certain medications. Some nucleoside analogues pose serious risks, leading to severe liver issues and lactic acidosis.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Pharmacology

Background:

  • Fatty liver disease (steatosis) is common in individuals with human immunodeficiency virus (HIV).
  • Multiple factors contribute to fatty liver in HIV, including HIV itself, nucleoside analogue use, viral hepatitis, alcohol, diabetes, and obesity.
  • Nucleoside analogues are a growing concern due to fatal cases of severe macrosteatosis, lactic acidosis, and hepatomegaly.

Purpose of the Study:

  • To explore the multifactorial causes of fatty liver in HIV-infected individuals.
  • To highlight the risks associated with nucleoside analogue use in HIV patients.
  • To identify conditions leading to rapid hepatic failure or cirrhosis in this population.

Main Methods:

  • Review of existing literature on HIV, steatosis, and antiretroviral therapies.

Related Experiment Videos

  • Analysis of reported cases linking nucleoside analogues to severe hepatic complications.
  • Examination of the additive effects of various risk factors on liver health in HIV patients.

    • Main Results:

    • HIV, nucleoside analogues, hepatitis B/C, alcohol, diabetes, and obesity are key contributors to fatty liver in HIV.
    • Fatalities linked to nucleoside analogues include severe macrosteatosis, lactic acidosis, and hepatomegaly.
    • Other antiretrovirals and infections can cause hepatic injury without steatosis, exacerbating liver issues.

    Conclusions:

    • The combination of risk factors significantly increases the prevalence of hepatic abnormalities in HIV-infected individuals.
    • Further research is needed to define the specific conditions that precipitate rapid progression to hepatic failure or cirrhosis.
    • Understanding these factors is crucial for managing liver health in the HIV population.